An exploratory study to determine the genetic polymorphisms or mutations associated with type 1 diabetes and interstitial lung disease induced by immune checkpoint inhibitor; nivolumab
Not Applicable
Recruiting
- Conditions
- type 1 diabetes interstitial lung disease
- Registration Number
- JPRN-UMIN000030495
- Lead Sponsor
- agasaki University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Not provided
Exclusion Criteria
The patient whom the researcher consider to be inappropriate for the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Allele frequency of causal variants or mutations associated with immune-related adverse events of nivolumab
- Secondary Outcome Measures
Name Time Method